{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T15:59:08Z","timestamp":1719849548449},"reference-count":74,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2018.0848","type":"journal-article","created":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T07:46:56Z","timestamp":1544082416000},"source":"Crossref","is-referenced-by-count":5,"title":["Hematological Malignancies in Adults With a Family Predisposition"],"prefix":"10.3238","author":[{"given":"Tilmann","family":"Bochtler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg-Martin","family":"Haag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Schott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Kloor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alwin","family":"Kr\u00e4mer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten","family":"M\u00fcller-Tidow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11437","published-online":{"date-parts":[[2018,12,14]]},"reference":[{"key":"10.3238\/arztebl.2018.0848_ref1","doi-asserted-by":"crossref","unstructured":"Steinke V, Engel C, Buttner R, Schackert HK, Schmiegel WH, Propping P: Hereditary nonpolyposis colorectal cancer (HNPCC)\/lynch syndrome. Dtsch Arztebl Int 2013; 110: 32\u20138","DOI":"10.3238\/arztebl.2013.0032"},{"key":"10.3238\/arztebl.2018.0848_ref2","doi-asserted-by":"crossref","unstructured":"Lax SF: Hereditary breast and ovarian cancer. Pathologe 2017; 38: 149\u201355","DOI":"10.1007\/s00292-017-0298-5"},{"key":"10.3238\/arztebl.2018.0848_ref3","doi-asserted-by":"crossref","unstructured":"DiNardo CD, Bannon SA, Routbort M, et al.: Evaluation of patients and families with concern for predispositions to hematologic malignancies within the hereditary hematologic malignancy clinic (HHMC). Clin Lymphoma Myeloma Leuk 2016; 16: 417\u201328e2.","DOI":"10.1016\/j.clml.2016.04.001"},{"key":"10.3238\/arztebl.2018.0848_ref4","doi-asserted-by":"crossref","unstructured":"Porter C: Germ line mutations associated with leukemias. Hematology 2016: 302\u20138","DOI":"10.1182\/asheducation-2016.1.302"},{"key":"10.3238\/arztebl.2018.0848_ref5","doi-asserted-by":"crossref","unstructured":"Similuk M, Rao VK, Churpek J, Lenardo M: Predispositions to lymphoma: a practical review for genetic counselors. J Genet Couns 2016; 25: 1157\u201370","DOI":"10.1007\/s10897-016-9979-0"},{"key":"10.3238\/arztebl.2018.0848_ref6","doi-asserted-by":"crossref","unstructured":"Churpek JE: Familial myelodysplastic syndrome\/acute myeloid leukemia. Best Pract Res Clin Haematol 2017; 30: 287\u20139","DOI":"10.1016\/j.beha.2017.10.002"},{"key":"10.3238\/arztebl.2018.0848_ref7","doi-asserted-by":"crossref","unstructured":"University of Chicago Hematopoietic Malignancies Cancer Risk Team: How I diagnose and manage individuals at risk for inherited myeloid malignancies. Blood 2016; 128: 1800\u201313","DOI":"10.1182\/blood-2016-05-670240"},{"key":"10.3238\/arztebl.2018.0848_ref8","doi-asserted-by":"crossref","unstructured":"Furutani E, Shimamura A: Germline genetic predisposition to hematologic malignancy. J Clin Oncol 2017; 35: 1018\u201328","DOI":"10.1200\/JCO.2016.70.8644"},{"key":"10.3238\/arztebl.2018.0848_ref9","doi-asserted-by":"crossref","unstructured":"Zhang MY, Keel SB, Walsh T, et al.: Genomic analysis of bone marrow failure and myelodysplastic syndromes reveals phenotypic and diagnostic complexity. Haematologica 2015; 100: 42\u20138","DOI":"10.3324\/haematol.2014.113456"},{"key":"10.3238\/arztebl.2018.0848_ref10","doi-asserted-by":"crossref","unstructured":"Keel SB, Scott A, Sanchez-Bonilla M, et al.: Genetic features of myelodysplastic syndrome and aplastic anemia in pediatric and young adult patients. Haematologica 2016; 101: 1343\u201350","DOI":"10.3324\/haematol.2016.149476"},{"key":"10.3238\/arztebl.2018.0848_ref11","doi-asserted-by":"crossref","unstructured":"Narumi S, Amano N, Ishii T, et al.: SAMD9 mutations cause a novel multisystem disorder, MIRAGE syndrome, and are associated with loss of chromosome 7. Nat Genet 2016; 48: 792\u20137","DOI":"10.1038\/ng.3569"},{"key":"10.3238\/arztebl.2018.0848_ref12","doi-asserted-by":"crossref","unstructured":"Jeffries L, Shima H, Ji W, et al.: A novel SAMD9 mutation causing MIRAGE syndrome: an expansion and review of phenotype, dysmorphology, and natural history. Am J Med Genet A 2018; 176: 415\u201320","DOI":"10.1002\/ajmg.a.38557"},{"key":"10.3238\/arztebl.2018.0848_ref13","doi-asserted-by":"crossref","unstructured":"Nickels EM, Soodalter J, Churpek JE, Godley LA: Recognizing familial myeloid leukemia in adults. Ther Adv Hematol 2013; 4: 254\u201369","DOI":"10.1177\/2040620713487399"},{"key":"10.3238\/arztebl.2018.0848_ref14","doi-asserted-by":"crossref","unstructured":"Shimamura A, Alter BP: Pathophysiology and management of inherited bone marrow failure syndromes. Blood Rev 2010; 24: 101\u201322","DOI":"10.1016\/j.blre.2010.03.002"},{"key":"10.3238\/arztebl.2018.0848_ref15","doi-asserted-by":"crossref","unstructured":"Bannon SA, DiNardo CD: Hereditary predispositions to myelodysplastic syndrome. Int J Mol Sci 2016; 17","DOI":"10.3390\/ijms17060838"},{"key":"10.3238\/arztebl.2018.0848_ref16","unstructured":"Chompret A, Brugieres L, Ronsin M, et al.: P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer 2000; 82: 1932\u20137"},{"key":"10.3238\/arztebl.2018.0848_ref17","doi-asserted-by":"crossref","unstructured":"Bougeard G, Renaux-Petel M, Flaman JM, et al.: Revisiting li-fraumeni syndrome from TP53 mutation carriers. J Clin Oncol 2015; 33: 2345\u201352 CrossRef","DOI":"10.1200\/JCO.2014.59.5728"},{"key":"10.3238\/arztebl.2018.0848_ref18","doi-asserted-by":"crossref","unstructured":"Valdez JM, Nichols KE, Kesserwan C: Li-fraumeni syndrome: a paradigm for the understanding of hereditary cancer predisposition. Br J Haematol 2017; 176: 539\u201352","DOI":"10.1111\/bjh.14461"},{"key":"10.3238\/arztebl.2018.0848_ref19","doi-asserted-by":"crossref","unstructured":"Suarez F, Mahlaoui N, Canioni D, et al.: Incidence, presentation, and prognosis of malignancies in ataxia-telangiectasia: a report from the French national registry of primary immune deficiencies. J Clin Oncol 2015; 33: 202\u20138","DOI":"10.1200\/JCO.2014.56.5101"},{"key":"10.3238\/arztebl.2018.0848_ref20","doi-asserted-by":"crossref","unstructured":"Alter BP: Inherited bone marrow failure syndromes: considerations pre- and posttransplant. Blood 2017; 130: 2257\u201364","DOI":"10.1182\/blood-2017-05-781799"},{"key":"10.3238\/arztebl.2018.0848_ref21","doi-asserted-by":"crossref","unstructured":"van Os NJ, Roeleveld N, Weemaes CM, et al.: Health risks for ataxia-telangiectasia mutated heterozygotes: a systematic review, meta-analysis and evidence-based guideline. Clin Genet 2016; 90: 105\u201317","DOI":"10.1111\/cge.12710"},{"key":"10.3238\/arztebl.2018.0848_ref22","doi-asserted-by":"crossref","unstructured":"Renault AL, Mebirouk N, Cavaciuti E, et al.: Telomere length, ATM mutation status and cancer risk in ataxia-telangiectasia families. Carcinogenesis 2017; 38: 994\u20131003","DOI":"10.1093\/carcin\/bgx074"},{"key":"10.3238\/arztebl.2018.0848_ref23","doi-asserted-by":"crossref","unstructured":"Smith ML, Cavenagh JD, Lister TA, Fitzgibbon J: Mutation of CEBPA in familial acute myeloid leukemia. N Engl J Med 2004; 351: 2403\u20137","DOI":"10.1056\/NEJMoa041331"},{"key":"10.3238\/arztebl.2018.0848_ref24","doi-asserted-by":"crossref","unstructured":"Sellick GS, Spendlove HE, Catovsky D, Pritchard-Jones K, Houlston RS: Further evidence that germline CEBPA mutations cause dominant inheritance of acute myeloid leukaemia. Leukemia 2005; 19: 1276\u20138","DOI":"10.1038\/sj.leu.2403788"},{"key":"10.3238\/arztebl.2018.0848_ref25","doi-asserted-by":"crossref","unstructured":"Pabst T, Eyholzer M, Haefliger S, Schardt J, Mueller BU: Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia. J Clin Oncol 2008; 26: 5088\u201393","DOI":"10.1200\/JCO.2008.16.5563"},{"key":"10.3238\/arztebl.2018.0848_ref26","doi-asserted-by":"crossref","unstructured":"Tawana K, Wang J, Renneville A, et al.: Disease evolution and outcomes in familial AML with germline CEBPA mutations. Blood 2015; 126: 1214\u201323","DOI":"10.1182\/blood-2015-05-647172"},{"key":"10.3238\/arztebl.2018.0848_ref27","doi-asserted-by":"crossref","unstructured":"Schlegelberger B, Heller PG: RUNX1 deficiency (familial platelet disorder with predisposition to myeloid leukemia, FPDMM). Semin Hematol 2017; 54: 75\u201380","DOI":"10.1053\/j.seminhematol.2017.04.006"},{"key":"10.3238\/arztebl.2018.0848_ref28","doi-asserted-by":"crossref","unstructured":"Sood R, Kamikubo Y, Liu P: Role of RUNX1 in hematological malignancies. Blood 2017; 129: 2070\u201382","DOI":"10.1182\/blood-2016-10-687830"},{"key":"10.3238\/arztebl.2018.0848_ref29","doi-asserted-by":"crossref","unstructured":"Hayashi Y, Harada Y, Huang G, Harada H: Myeloid neoplasms with germ line RUNX1 mutation. Int J Hematol 2017; 106: 183\u20138","DOI":"10.1007\/s12185-017-2258-5"},{"key":"10.3238\/arztebl.2018.0848_ref30","doi-asserted-by":"crossref","unstructured":"Feurstein S, Godley LA: Germline ETV6 mutations and predisposition to hematological malignancies. Int J Hematol 2017; 106: 189\u201395","DOI":"10.1007\/s12185-017-2259-4"},{"key":"10.3238\/arztebl.2018.0848_ref31","doi-asserted-by":"crossref","unstructured":"Polprasert C, Schulze I, Sekeres MA, et al.: Inherited and somatic defects in DDX41 in myeloid neoplasms. Cancer Cell 2015; 27: 658\u201370","DOI":"10.1016\/j.ccell.2015.03.017"},{"key":"10.3238\/arztebl.2018.0848_ref32","doi-asserted-by":"crossref","unstructured":"Lewinsohn M, Brown AL, Weinel LM, et al.: Novel germ line DDX41 mutations define families with a lower age of MDS\/AML onset and lymphoid malignancies. Blood 2016; 127: 1017\u201323","DOI":"10.1182\/blood-2015-10-676098"},{"key":"10.3238\/arztebl.2018.0848_ref33","doi-asserted-by":"crossref","unstructured":"Maciejewski JP, Padgett RA, Brown AL, Muller-Tidow C: DDX41-related myeloid neoplasia. Semin Hematol 2017; 54: 94\u20137","DOI":"10.1053\/j.seminhematol.2017.04.007"},{"key":"10.3238\/arztebl.2018.0848_ref34","doi-asserted-by":"crossref","unstructured":"Wlodarski MW, Hirabayashi S, Pastor V, et al.: Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents. Blood 2016; 127: 1387\u201397; quiz 518","DOI":"10.1182\/blood-2015-09-669937"},{"key":"10.3238\/arztebl.2018.0848_ref35","doi-asserted-by":"crossref","unstructured":"Davidsson J, Puschmann A, Tedgard U, Bryder D, Nilsson L, Cammenga J: SAMD9 and SAMD9L in inherited predisposition to ataxia, pancytopenia, and myeloid malignancies. Leukemia 2018","DOI":"10.1038\/s41375-018-0074-4"},{"key":"10.3238\/arztebl.2018.0848_ref36","doi-asserted-by":"crossref","unstructured":"Niemeyer CM, Mecucci C: Practical considerations for diagnosis and management of patients and carriers. Semin Hematol 2017; 54: 69\u201374.","DOI":"10.1053\/j.seminhematol.2017.04.002"},{"key":"10.3238\/arztebl.2018.0848_ref37","doi-asserted-by":"crossref","unstructured":"Godley LA, Shimamura A: Genetic predisposition to hematologic malignancies: management and surveillance. Blood 2017; 130: 424\u201332","DOI":"10.1182\/blood-2017-02-735290"},{"key":"10.3238\/arztebl.2018.0848_ref38","doi-asserted-by":"crossref","unstructured":"DiNardo CD: Getting a handle on hereditary CEBPA mutations. Blood 2015; 126: 1156\u20138","DOI":"10.1182\/blood-2015-07-657908"},{"key":"10.3238\/arztebl.2018.0848_ref39","doi-asserted-by":"crossref","unstructured":"Arber DA, Orazi A, Hasserjian R, et al.: The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127: 2391\u2013405","DOI":"10.1182\/blood-2016-03-643544"},{"key":"10.3238\/arztebl.2018.0848_ref40","doi-asserted-by":"crossref","unstructured":"Richards S, Aziz N, Bale S, et al.: Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17: 405\u201324","DOI":"10.1038\/gim.2015.30"},{"key":"10.3238\/arztebl.2018.0848_ref41","doi-asserted-by":"crossref","unstructured":"Butturini A, Gale RP, Verlander PC, Adler-Brecher B, Gillio AP, Auerbach AD: Hematologic abnormalities in fanconi anemia: an international fanconi anemia registry study. Blood 1994; 84: 1650\u20135","DOI":"10.1182\/blood.V84.5.1650.1650"},{"key":"10.3238\/arztebl.2018.0848_ref42","doi-asserted-by":"crossref","unstructured":"Tischkowitz M, Xia B, Sabbaghian N, et al.: Analysis of PALB2\/FANCN-associated breast cancer families. Proc Natl Acad Sci U S A 2007; 104: 6788\u201393","DOI":"10.1073\/pnas.0701724104"},{"key":"10.3238\/arztebl.2018.0848_ref43","doi-asserted-by":"crossref","unstructured":"Berwick M, Satagopan JM, Ben-Porat L, et al.: Genetic heterogeneity among fanconi anemia heterozygotes and risk of cancer. Cancer Res 2007; 67: 9591\u20136","DOI":"10.1158\/0008-5472.CAN-07-1501"},{"key":"10.3238\/arztebl.2018.0848_ref44","doi-asserted-by":"crossref","unstructured":"Laitman Y, Boker-Keinan L, Berkenstadt M, et al.: The risk for developing cancer in Israeli ATM, BLM, and FANCC heterozygous mutation carriers. Cancer Genet 2016; 209: 70\u20134","DOI":"10.1016\/j.cancergen.2015.12.006"},{"key":"10.3238\/arztebl.2018.0848_ref45","doi-asserted-by":"crossref","unstructured":"Przychodzen B, Makishima H, Sekeres MA, et al.: Fanconi anemia germline variants as susceptibility factors in aplastic anemia, MDS and AML. Oncotarget 2018; 9: 2050\u20137","DOI":"10.18632\/oncotarget.23328"},{"key":"10.3238\/arztebl.2018.0848_ref46","doi-asserted-by":"crossref","unstructured":"Dror Y, Donadieu J, Koglmeier J, et al.: Draft consensus guidelines for diagnosis and treatment of shwachman-diamond syndrome. Ann N Y Acad Sci 2011; 1242: 40\u201355","DOI":"10.1111\/j.1749-6632.2011.06349.x"},{"key":"10.3238\/arztebl.2018.0848_ref47","doi-asserted-by":"crossref","unstructured":"Salmon A, Amikam D, Sodha N, et al.: Rapid development of post-radiotherapy sarcoma and breast cancer in a patient with a novel germline \u201ade-novo\u2018 TP53 mutation. Clin Oncol (R Coll Radiol) 2007; 19: 490\u20133","DOI":"10.1016\/j.clon.2007.05.001"},{"key":"10.3238\/arztebl.2018.0848_ref48","doi-asserted-by":"crossref","unstructured":"Heymann S, Delaloge S, Rahal A, et al.: Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with li-fraumeni syndrome. Radiat Oncol 2010; 5: 104","DOI":"10.1186\/1748-717X-5-104"},{"key":"10.3238\/arztebl.2018.0848_ref49","doi-asserted-by":"crossref","unstructured":"Kamihara J, Rana HQ, Garber JE: Germline TP53 mutations and the changing landscape of li-fraumeni syndrome. Hum Mutat 2014; 35: 654\u201362","DOI":"10.1002\/humu.22559"},{"key":"10.3238\/arztebl.2018.0848_ref50","doi-asserted-by":"crossref","unstructured":"Saida S: Predispositions to leukemia in down syndrome and other hereditary disorders. Curr Treat Options Oncol 2017; 18: 41","DOI":"10.1007\/s11864-017-0485-x"},{"key":"10.3238\/arztebl.2018.0848_ref51","doi-asserted-by":"crossref","unstructured":"Babushok DV, Bessler M, Olson TS: Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults. Leuk Lymphoma 2016; 57: 520\u201336","DOI":"10.3109\/10428194.2015.1115041"},{"key":"10.3238\/arztebl.2018.0848_ref52","doi-asserted-by":"crossref","unstructured":"Berger G, van den Berg E, Sikkema-Raddatz B, et al.: Re-emergence of acute myeloid leukemia in donor cells following allogeneic transplantation in a family with a germline DDX41 mutation. Leukemia 2017; 31: 520\u20132","DOI":"10.1038\/leu.2016.310"},{"key":"10.3238\/arztebl.2018.0848_ref53","doi-asserted-by":"crossref","unstructured":"Rumi E: Familial chronic myeloproliferative disorders: the state of the art. Hematol Oncol 2008; 26: 131\u20138","DOI":"10.1002\/hon.863"},{"key":"10.3238\/arztebl.2018.0848_ref54","doi-asserted-by":"crossref","unstructured":"Landgren O, Goldin LR, Kristinsson SY, Helgadottir EA, Samuelsson J, Bjorkholm M: Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden. Blood 2008; 112: 2199\u2013204","DOI":"10.1182\/blood-2008-03-143602"},{"key":"10.3238\/arztebl.2018.0848_ref55","doi-asserted-by":"crossref","unstructured":"Rumi E, Passamonti F, Della Porta MG, et al.: Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation. J Clin Oncol 2007; 25: 5630\u20135","DOI":"10.1200\/JCO.2007.12.6896"},{"key":"10.3238\/arztebl.2018.0848_ref56","doi-asserted-by":"crossref","unstructured":"Cerhan JR, Slager SL: Familial predisposition and genetic risk factors for lymphoma. Blood 2015; 126: 2265\u201373","DOI":"10.1182\/blood-2015-04-537498"},{"key":"10.3238\/arztebl.2018.0848_ref57","doi-asserted-by":"crossref","unstructured":"Marron JM, Joffe S: Ethical considerations in genomic testing for hematologic disorders. Blood 2017; 130: 460\u20135","DOI":"10.1182\/blood-2017-01-734558"},{"key":"10.3238\/arztebl.2018.0848_ref58","doi-asserted-by":"crossref","unstructured":"Qian M, Cao X, Devidas M, et al.: TP53 germline variations influence\u00a0the predisposition and prognosis of B-cell acute lymphoblastic leukemia in children. J Clin Oncol 2018; 36: 591\u20139","DOI":"10.1200\/JCO.2017.75.5215"},{"key":"10.3238\/arztebl.2018.0848_ref59","doi-asserted-by":"crossref","unstructured":"Green CL, Tawana K, Hills RK, et al.: GATA2 mutations in sporadic and familial acute myeloid leukaemia patients with CEBPA mutations. Br J Haematol 2013; 161: 701\u20135","DOI":"10.1111\/bjh.12317"},{"key":"10.3238\/arztebl.2018.0848_ref60","doi-asserted-by":"crossref","unstructured":"Spinner MA, Sanchez LA, Hsu AP, et al.: GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. Blood 2014; 123: 809\u201321","DOI":"10.1182\/blood-2013-07-515528"},{"key":"10.3238\/arztebl.2018.0848_ref61","doi-asserted-by":"crossref","unstructured":"Wouters BJ, Lowenberg B, Erpelinck-Verschueren CA, van Putten WL, Valk PJ, Delwel R: Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood 2009; 113: 3088\u201391","DOI":"10.1182\/blood-2008-09-179895"},{"key":"10.3238\/arztebl.2018.0848_ref62","doi-asserted-by":"crossref","unstructured":"Gaidzik VI, Teleanu V, Papaemmanuil E, et al.: RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features. Leukemia 2016; 30: 2160\u20138","DOI":"10.1038\/leu.2016.126"},{"key":"10.3238\/arztebl.2018.0848_ref63","doi-asserted-by":"crossref","unstructured":"Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN: EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from lynch syndrome. Genet Med 2009; 11: 42\u201365","DOI":"10.1097\/GIM.0b013e31818fa2db"},{"key":"10.3238\/arztebl.2018.0848_ref64","doi-asserted-by":"crossref","unstructured":"Kloor M, Huth C, Voigt AY, et al.: Prevalence of mismatch repair-deficient crypt foci in lynch syndrome: a pathological study. Lancet Oncol 2012; 13: 598\u2013606","DOI":"10.1016\/S1470-2045(12)70109-2"},{"key":"10.3238\/arztebl.2018.0848_ref65","doi-asserted-by":"crossref","unstructured":"Syngal S, Brand RE, Church JM, et al.: ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol 2015; 110: 223\u201362; quiz 63.","DOI":"10.1038\/ajg.2014.435"},{"key":"10.3238\/arztebl.2018.0848_ref66","unstructured":"Jass JR, Smyrk TC, Stewart SM, Lane MR, Lanspa SJ, Lynch HT: Pathology of hereditary non-polyposis colorectal cancer. Anticancer Res 1994; 14: 1631\u20134"},{"key":"10.3238\/arztebl.2018.0848_ref67","unstructured":"Ruschoff J, Roggendorf B, Brasch F, et al.: Molecular pathology in hereditary colorectal cancer. Recommendations of the collaborative German study group on hereditary colorectal cancer funded by the German Cancer Aid (Deutsche Krebshilfe). Pathologe 2004; 25: 178\u201392."},{"key":"10.3238\/arztebl.2018.0848_ref68","doi-asserted-by":"crossref","unstructured":"Overman MJ, McDermott R, Leach JL, et al.: Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 2017; 18: 1182\u201391","DOI":"10.1016\/S1470-2045(17)30422-9"},{"key":"10.3238\/arztebl.2018.0848_ref69","doi-asserted-by":"crossref","unstructured":"Spier I, Holzapfel S, Steinke V, Aretz S: Genetik gastrointestinaler Tumoren \u2013 Welche Folgen haben Keimbahnmutationen? Der Gastroenterologe 2013; 04\/2013.","DOI":"10.1007\/s11377-013-0764-4"},{"key":"10.3238\/arztebl.2018.0848_ref70","doi-asserted-by":"crossref","unstructured":"Rau TT, Dawson H, Hartmann A, Ruschoff J: Hereditary colorectal cancer: an update on genetics and entities in terms of differential diagnosis. Pathologe 2017; 38: 156\u201363.","DOI":"10.1007\/s00292-017-0294-9"},{"key":"10.3238\/arztebl.2018.0848_ref71","doi-asserted-by":"crossref","unstructured":"Mavaddat N, Barrowdale D, Andrulis IL, et al.: Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the consortium of investigators of modifiers of BRCA1\/2 (CIMBA). Cancer Epidemiol Biomarkers Prev 2012; 21: 134\u201347","DOI":"10.1016\/j.yobg.2012.05.049"},{"key":"10.3238\/arztebl.2018.0848_ref72","unstructured":"Hahnen E, Rhiem K, Schmutzler R: Genpanelanalysen: Spannungsfeld zwischen kommerziellem Interesse und Patientennutzen. Dtsch Arztebl 2016; 113: A-2028"},{"key":"10.3238\/arztebl.2018.0848_ref73","unstructured":"Zylka-Menhorn V: Famili\u00e4rer Brustkrebs: Wie neue Brustkrebsgene zu bewerten sind. Dtsch Arztebl 2017; 114: A-894"},{"key":"10.3238\/arztebl.2018.0848_ref74","doi-asserted-by":"crossref","unstructured":"Hartmann A: Pathologie famili\u00e4rer Tumorsyndrome. Pathologe 2017; 38: 143\u20138","DOI":"10.1007\/s00292-017-0299-4"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2018.0848","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T14:22:01Z","timestamp":1638800521000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2018.0848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,14]]},"references-count":74,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2018.0848","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,14]]}}}